| Literature DB >> 8380338 |
L M Giroux1, J Davignon, M Naruszewicz.
Abstract
Human monocyte-derived macrophages treated with increasing concentrations of the HMG-CoA reductase inhibitor, simvastatin, showed a dose-dependent decrease in superoxide formation in response to activation by phorbol myristate acetate. As a consequence, they oxidized LDL much less than untreated cells. Addition of exogenous mevalonic acid to simvastatin-treated macrophages restored their ability for superoxide production and for oxidative modification of LDL. These results indicate that simvastatin might prevent atherosclerosis by additional mechanisms besides its hypocholesterolemic activity.Entities:
Mesh：
Substances：
Year: 1993 PMID： 8380338 DOI： 10.1016/0005-2760(93)90145-y
Source DB: PubMed Journal: Biochim Biophys Acta ISSN： 0006-3002